Cogent Biosciences (COGT)

Company Profile

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent Biosciences is headquartered in Cambridge, MA.

Company profile

Ticker

COGT

Exchange

NASDAQ

Website

www.cogentbio.com

CEO

Andrew R. Robbins

Incorporated

Delaware

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies ...

Former names

Unum Therapeutics Inc., Unum Therapeutics, Inc.

SEC CIK

0001622229

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Mono Inc. • Kiq Bio LLC ...

COGT stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$21.50

Low target

$20.00

High target

$23.00

Latest filings (excl ownership)

View all

S-8

Registration of securities for employees

14 Mar 23

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results

14 Mar 23

S-3ASR

Automatic shelf registration

10 Feb 23

8-K

Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating

14 Nov 22

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results

9 Aug 22

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results

9 Aug 22

8-K/A

Entry into a Material Definitive Agreement

16 Jun 22

Latest ownership filings

View all

Venrock Healthcare Capital Partners II, L.P.

14 Feb 23

SC 13G/A

RA CAPITAL MANAGEMENT, L.P.

TCG Crossover GP I, LLC

14 Feb 23

SC 13G/A

EVENTIDE ASSET MANAGEMENT, LLC

14 Feb 23

Financial summary

Financial statements Chart COGT financial data

Quarter (USD)	Dec 22	Sep 22	Jun 22	Mar 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	141.14 mm	141.14 mm	141.14 mm	141.14 mm	141.14 mm	141.14 mm
Cash burn (monthly)	227.33 k	6.65 mm	14.58 mm	12.32 mm	9.80 mm	9.89 mm
Cash used (since last report)	649.09 k	18.99 mm	41.63 mm	35.18 mm	27.99 mm	28.23 mm
Cash remaining	140.49 mm	122.15 mm	99.51 mm	105.96 mm	113.15 mm	112.91 mm
Runway (months of cash)	618.0	18.4	6.8	8.6	11.5	11.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2022

COGT institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	143	140	+2.1%
Opened positions	24	35	-31.4%
Closed positions	21	14	+50.0%
Increased positions	53	45	+17.8%
Reduced positions	40	36	+11.1%

13F shares	Current	Prev Q	Change
Total value	800.68 bn	1.15 bn	+69771.6%
Total shares	96.20 mm	90.80 mm	+5.9%
Total puts	1.20 k	22.80 k	-94.7%
Total calls	59.60 k	93.30 k	-36.1%
Total put/call ratio	0.0	0.2	-91.8%

Largest owners	Shares	Value	Change
Venrock Healthcare Capital Partners II	7.31 mm	$0.00	+69.9%
Ra Capital Management	6.00 mm	$69.35 bn	+49.5%
BLK Blackrock	4.95 mm	$57.18 bn	+7.6%
Commodore Capital	4.32 mm	$50.02 bn	0.0%
STT State Street	4.26 mm	$49.26 bn	NEW
VR Adviser	4.04 mm	$46.68 bn	0.0%
TCG Crossover GP I	3.63 mm	$0.00	NEW
TCG Crossover Management	3.63 mm	$41.97 bn	+4.3%
Vanguard	3.47 mm	$40.06 bn	+8.9%
Perceptive Advisors	3.21 mm	$37.08 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
STT State Street	4.26 mm	+4.26 mm	NEW
TCG Crossover GP I	3.63 mm	+3.63 mm	NEW
Venrock Healthcare Capital Partners II	7.31 mm	+3.01 mm	+69.9%
Flynn James E	2.97 mm	-2.91 mm	-49.5%
Biotechnology Value Fund L P	984.82 k	-2.13 mm	-68.4%
Ra Capital Management	6.00 mm	+1.99 mm	+49.5%
Marshall Wace	1.48 mm	+1.48 mm	NEW
Avidity Partners Management	0.00	-1.36 mm	EXIT
BVF	984.82 k	-1.10 mm	-52.8%
Logos Global Management	1.10 mm	+1.10 mm	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

COGT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
13 Feb 23	Robbins Andrew R	Stock Option Common Stock	Grant	Acquire A	No	No	13.63	525,000	7.16 mm	525,000
13 Feb 23	Jessica Sachs	Stock Option Common Stock	Grant	Acquire A	No	No	13.63	160,000	2.18 mm	160,000
13 Feb 23	Green John L.	Stock Option Common Stock	Grant	Acquire A	No	No	13.63	150,000	2.04 mm	150,000
13 Feb 23	Evan Kearns	Stock Option Common Stock	Grant	Acquire A	No	No	13.63	140,000	1.91 mm	140,000
13 Feb 23	John Edward Robinson	Stock Option Common Stock	Grant	Acquire A	No	No	13.63	160,000	2.18 mm	160,000